JP2014500307A5 - - Google Patents

Download PDF

Info

Publication number
JP2014500307A5
JP2014500307A5 JP2013545584A JP2013545584A JP2014500307A5 JP 2014500307 A5 JP2014500307 A5 JP 2014500307A5 JP 2013545584 A JP2013545584 A JP 2013545584A JP 2013545584 A JP2013545584 A JP 2013545584A JP 2014500307 A5 JP2014500307 A5 JP 2014500307A5
Authority
JP
Japan
Prior art keywords
alkyl
aryl
group
independently
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013545584A
Other languages
English (en)
Japanese (ja)
Other versions
JP5992435B2 (ja
JP2014500307A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2011/055730 external-priority patent/WO2012085789A1/en
Publication of JP2014500307A publication Critical patent/JP2014500307A/ja
Publication of JP2014500307A5 publication Critical patent/JP2014500307A5/ja
Application granted granted Critical
Publication of JP5992435B2 publication Critical patent/JP5992435B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

JP2013545584A 2010-12-21 2011-12-16 循環からの生体分子の除去剤 Active JP5992435B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10196092.0 2010-12-21
EP10196092 2010-12-21
PCT/IB2011/055730 WO2012085789A1 (en) 2010-12-21 2011-12-16 Agents for clearing biomolecules from circulation

Publications (3)

Publication Number Publication Date
JP2014500307A JP2014500307A (ja) 2014-01-09
JP2014500307A5 true JP2014500307A5 (cg-RX-API-DMAC7.html) 2015-10-29
JP5992435B2 JP5992435B2 (ja) 2016-09-14

Family

ID=43530614

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013545584A Active JP5992435B2 (ja) 2010-12-21 2011-12-16 循環からの生体分子の除去剤

Country Status (6)

Country Link
US (1) US9427482B2 (cg-RX-API-DMAC7.html)
EP (1) EP2654796A1 (cg-RX-API-DMAC7.html)
JP (1) JP5992435B2 (cg-RX-API-DMAC7.html)
CN (1) CN103328008B (cg-RX-API-DMAC7.html)
RU (1) RU2013133813A (cg-RX-API-DMAC7.html)
WO (1) WO2012085789A1 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103732256A (zh) * 2011-05-16 2014-04-16 皇家飞利浦有限公司 生物正交药物活化
US20150297741A1 (en) * 2012-11-22 2015-10-22 Tagworks Pharmaceuticals B.V. Bio-orthogonal drug activation
FI2922574T3 (fi) * 2012-11-22 2023-08-11 Tagworks Pharmaceuticals B V Kemiallisesti pilkkoutuva ryhmä
WO2014081300A1 (en) * 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Channel protein activatable liposomes
WO2014081299A1 (en) * 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Activatable liposomes
US10130711B2 (en) * 2013-06-19 2018-11-20 The Regents Of The University Of California Chemical structures for localized delivery of therapeutic agents
EP3116525B1 (en) 2014-03-14 2021-06-23 The Regents of the University of California Tco conjugates and methods for delivery of therapeutic agents
US10179775B2 (en) 2014-08-11 2019-01-15 The General Hospital Corporation Cyclooctenes for bioorthogonol reactions
US20180194769A1 (en) 2015-07-06 2018-07-12 Rodin Therapeutics, Inc. Hetero-halo inhibitors of histone deacetylase
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
US10828373B2 (en) 2015-09-10 2020-11-10 Tambo, Inc. Bioorthogonal compositions
WO2018004338A1 (en) 2016-06-27 2018-01-04 Tagworks Pharmaceuticals B.V. Cleavable tetrazine used in bio-orthogonal drug activation
US10222346B2 (en) * 2017-01-09 2019-03-05 National Research Council Of Canada Decomposable S-tetrazine based polymers for single walled carbon nanotube applications
JP6756925B2 (ja) 2017-01-11 2020-09-16 ロダン・セラピューティクス，インコーポレーテッド ヒストンデアセチラーゼの二環式阻害剤
EP3606559B1 (en) 2017-04-07 2024-06-05 Tambo, Inc. Bioorthogonal compositions
WO2019010299A1 (en) * 2017-07-06 2019-01-10 Memorial Sloan Kettering Cancer Center DOTA-HAPTENE COMPOSITIONS FOR RADIOIMMUNOTHERAPY PRECIBLED BY A BISPECIFIC ANTIGEN ANTI-DOTA / ANTI-TUMOR ANTIBODY
EP3651741A4 (en) 2017-07-14 2021-04-21 The Penn State Research Foundation Compositions and methods for targeted delivery of therapeutic and/or diagnostic species
SMT202200232T1 (it) 2017-08-07 2022-07-21 Alkermes Inc Inibitori biciclici di istone deacetilasi
KR20200130711A (ko) 2018-03-12 2020-11-19 메모리얼 슬로안 케터링 캔서 센터 이중특이적 결합제 및 이의 용도
FI3853234T3 (fi) 2018-09-18 2025-07-28 Nikang Therapeutics Inc Fuusioituja trisyklisiä rengasjohdannaisia SRC-homologia-2-fosfataasin estäjinä
IL289095A (en) 2019-06-17 2022-02-01 Tagworks Pharmaceuticals B V Activating components to cleave labels from biomolecules in vivo
ES2981364T3 (es) 2019-06-17 2024-10-08 Tagworks Pharmaceuticals B V Compuestos para liberación clic rápida y eficiente
CN121127267A (zh) * 2023-02-15 2025-12-12 泰克沃尔科斯制药有限公司 具有改进性质的四嗪
WO2025166289A1 (en) * 2024-01-31 2025-08-07 Oregon State University Tunable tetrazine amino acids for encodable protein labeling

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6075010A (en) 1992-06-09 2000-06-13 Neorx Corporation Small molecular weight ligand-hexose containing clearing agents
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US5326856A (en) 1992-04-09 1994-07-05 Cytogen Corporation Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding
US5624896A (en) 1992-06-09 1997-04-29 Neorx Corporation Clearing agents useful in pretargeting methods
US5616690A (en) 1992-06-09 1997-04-01 Neorx Corporation Hexose derivatized human serum albumin clearing agents
US20030129191A1 (en) 1992-12-23 2003-07-10 Neorx Corporation Pretargeting methods and compounds
DE69433343D1 (de) 1993-12-07 2003-12-24 Neorx Corp Pretargeting verfahren und mitteln
EP0743956A4 (en) 1993-12-07 1999-03-24 Neorx Corp Warping and averaging procedures
US5886143A (en) 1994-12-07 1999-03-23 Neorx Corporation Hepatic-directed compounds and reagents for preparation thereof
US6908903B1 (en) 1994-12-07 2005-06-21 Aletheon Pharmaceuticals, Inc. Cluster clearing agents
US6172045B1 (en) 1994-12-07 2001-01-09 Neorx Corporation Cluster clearing agents
CA2223261C (en) 1995-06-07 2010-05-11 Immunomedics, Inc. Improved delivery of diagnostic and therapeutic agents to a target site
US7052872B1 (en) 1999-06-22 2006-05-30 Immunomedics, Inc. Bi-specific antibodies for pre-targeting diagnosis and therapy
JP2008515876A (ja) 2004-10-07 2008-05-15 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ イメージング及び治療用のイメージング及び治療のエンドキットにおけるシュタウディンガーライゲーションの使用
WO2007039858A2 (en) 2005-10-04 2007-04-12 Koninklijke Philips Electronics N.V. Targeted imaging and/or therapy using the [3+2] azide-alkyne cycloaddition
EP3622968A1 (en) 2008-10-31 2020-03-18 The General Hospital Corporation Compositions and methods for delivering a substance to a biological target
DK2419142T3 (da) 2009-04-16 2020-02-10 Tagworks Pharmaceuticals B V Præmålretningskit, fremgangsmåde og deri anvendte midler
WO2010119382A1 (en) 2009-04-16 2010-10-21 Koninklijke Philips Electronics N.V. Pretargeting kit, method and agents used therein
KR20140038348A (ko) 2010-12-13 2014-03-28 바이오미메틱 세라퓨틱스, 엘엘씨 척추 유합 절차를 위한 조성물 및 방법

Similar Documents

Publication Publication Date Title
JP5992435B2 (ja) 循環からの生体分子の除去剤
JP2014500307A5 (cg-RX-API-DMAC7.html)
JP6368745B2 (ja) プレターゲットキット、プレターゲット方法及びその使用試薬
EP2419142B1 (en) Pretargeting kit, method and agents used therein
US9913921B2 (en) Pretargeting kit for imaging or therapy comprising a trans-cyclooctene dienophile and a diene
JP2014506869A5 (cg-RX-API-DMAC7.html)
CN102438656B (zh) 预靶向试剂盒、方法和其中使用的试剂
EP4424713A2 (en) Agents for cleaving labels from biomolecules in vivo
CN103269721B (zh) 预靶向试剂盒、方法和其中使用的试剂